This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Clinical Research Department

Cancer Research Department

Philadelphia, PA

Dialysis and Nephrology

Oncology Department

Las Vegas, NV

Department of Research and Evaluation

NRG Oncology

The main purpose of the study is to assess whether the study drug, LY4066434, is safe and tolerable when administered to participants with locally advanced or metastatic solid tumors with certain KRAS mutations. LY4066434 will be given alone or in combination with other treatments. The study will have 2 parts: monotherapy dose escalation and dose optimization. The study is expected to last up to approximately 5 years.

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

START Midwest

START San Antonio

Lilly

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

Plantation, FL

Detroit, MI

Neuro-Oncology Department

Pediatric Endocrinology Department

Newport Beach, CA

Beverly Hills, CA

Los Angeles, CA

Seattle, WA

Mirati Therapeutics

Study CA239-0006 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation.

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

Stephenson Cancer Center

Women´s Health Institute

Clinical Research Unit

Oncology Clinic - Clinical Trials Unit

Thoracic Oncology Clinic

Arcispedale Santa Maria Nuova - Cardiovascular Medicine

Clinical Trial Center

Neurology Department

Gleneagles Medical Centre

The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon or rectal cancer.

S0820, Adenoma and Second Primary Prevention Trial

Preventive Medicine

Wright-Patterson Medical Center

Hepatology Gastroenterology Clinic

UMC Hospital, Clinical Trials Office

SWOG Cancer Research Network

This is a multicenter, open-label, dose-escalation, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, pharmacokinetic (PK), pharmacodynamics, and immunogenicity of durvalumab (MEDI4736) in combination with monalizumab (IPH2201) in adult participants with selected advanced solid tumors and the combination of durvalumab and monalizumab (IPH2201) standard of care systemic therapy with or without biological agent and monalizumab (IPH2201) with biological agent administered to participants with recurrent or metastatic colorectal cancer (CRC).

A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

MedImmune

The study will assess the safety and efficacy of BXQ-350 plus modified FOLFOX7 (mFOLFOX7) and bevacizumab in participants who have newly diagnosed metastatic adenocarcinoma of the colon/rectum. The study will also evaluate if the administration of BXQ-350 with mFOLFOX7 and bevacizumab may diminish oxaliplatin induced sensory neurotoxicity, enabling participants to receive the total and planned doses of mFOLFOX7.

All participants will receive BXQ-350 by intravenous (IV) infusion along with standard of care doses of mFOLFOX and bevacizumab. The study is divided into two stages: Stage 1 will be open label and will enroll participants at increasing dose levels of BXQ-350 in order to determine the Stage 2 dose. Stage 2 will be blinded; participants will receive BXQ-350 at the established Stage 1 dose or placebo.

BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma

Bexion Pharmaceuticals

Find clinical trials for Colon Cancer in Birmingham, AL

Related conditions:

Colon Cancer trials near Birmingham, AL, USA:

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

S0820, Adenoma and Second Primary Prevention Trial (PACES)

A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma (ASIST)

Find clinical trials for Colon Cancer in .css-epvm6{white-space:nowrap;}Birmingham, AL

Related conditions:

Colon Cancer trials near Birmingham, AL, USA:

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

S0820, Adenoma and Second Primary Prevention Trial (PACES)

A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma (ASIST)

Find clinical trials for Colon Cancer in Birmingham, AL